Statin trials in progress: unanswered questions.
Five years ago, many critics questioned the value of lipid-lowering therapy. Today, the clinical benefits of statins are well documented, but the challenge remains to fully implement these benefits across the wide spectrum of the at-risk population, and continue to advance our understanding regarding the potential for the benefits of statins across an even broader range of select patient populations.
Davidson
M H
MH
Chicago Center for Clinical Research, Rush Presbyterian-St. Luke's, 515 North State Street, Suite 2700, Chicago, IL 60610, USA.
D000069059:Atorvastatin; D002986:Clinical Trials as Topic; D003327:Coronary Disease / Q000209:etiology / Q000517:prevention & control; D004359:Drug Therapy, Combination; D005229:Fatty Acids, Monounsaturated / Q000627:therapeutic use; D000077340:Fluvastatin; D006538:Heptanoic Acids / Q000627:therapeutic use; D006801:Humans; D000960:Hypolipidemic Agents / Q000627:therapeutic use*; D007211:Indoles / Q000627:therapeutic use; D008148:Lovastatin / Q000627:therapeutic use; D017035:Pravastatin / Q000627:therapeutic use; D011725:Pyridines / Q000627:therapeutic use; D011758:Pyrroles / Q000627:therapeutic use; D019821:Simvastatin / Q000627:therapeutic use
D005229:Fatty Acids, Monounsaturated; D006538:Heptanoic Acids; D000960:Hypolipidemic Agents; D007211:Indoles; D011725:Pyridines; D011758:Pyrroles; D000077340:Fluvastatin; D008148:Lovastatin; D000069059:Atorvastatin; D019821:Simvastatin; C086276:cerivastatin; D017035:Pravastatin